The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FIRST/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC).
 
Anne-Claire Hardy-Bessard
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Gilead Sciences; GlaxoSmithKline; MSD; Novartis; Pfizer; Regeneron
 
Eric Pujade-Lauraine
Employment - Arcagy-Gineco
Consulting or Advisory Role - AGENUS; Incyte
Research Funding - AstraZeneca (Inst)
Other Relationship - Arcagy-Gineco
 
Richard Moore
Honoraria - Fujirebio Diagnostics
Consulting or Advisory Role - Fujirebio Diagnostics
Research Funding - Angle
 
François Montestruc
No Relationships to Disclose
 
Andres Redondo
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; GlaxoSmithKline; MSD; Pharma&
Speakers' Bureau - Abbvie; AstraZeneca; GlaxoSmithKline; MSD; pharma&
Travel, Accommodations, Expenses - AstraZeneca
 
Mansoor Mirza
Stock and Other Ownership Interests - Karyopharm Therapeutics; Sera Prognostics
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Takeda; Zai Lab
Consulting or Advisory Role - Abbvie; Allarity Therapeutics; AstraZeneca; BIOCAD; BioNTech; Daiichi Sankyo; Eisai; GlaxoSmithKline; ImmunoGen/AbbVie; Incyte; Karyopharm Therapeutics; MSD; Regeneron; Zai Lab
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
Other Relationship - Karyopharm Therapeutics; Sera Prognostics
 
Nataliya Volodko
Honoraria - AstraZeneca; MSD
Speakers' Bureau - AstraZeneca; MSD
 
Tudor-Eliade Ciuleanu
Consulting or Advisory Role - A&D Pharma; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MagnaPharm; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; SERVIER; Takeda
Travel, Accommodations, Expenses - A&D Pharma; Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Servier
 
Lucy Gilbert
Honoraria - GlaxoSmithKline; Merck; Repare Therapeutics
Consulting or Advisory Role - Corcept Therapeutics; Eisai; GlaxoSmithKline; Immunogen; Kora Healthcare; Merck
Research Funding - Alkermes (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Corcept Therapeutics (Inst); Esperas Pharma (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Immunogen (Inst); IMV (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Repare Therapeutics (Inst); Roche (Inst); Seagen (Inst); Shattuck Labs (Inst); Sutro BioPharma Inc (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Corcept Therapeutics; Eisai; EndomEra; GlaxoSmithKline; GOG Foundation; Merck; Zentalis
 
Ram Eitan
No Relationships to Disclose
 
Flora Zagouri
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD; Novartis; Pfizer Hellas; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
 
Sandro Pignata
Honoraria - AstraZeneca; GlaxoSmithKline; MSD; Novartis; pfizer; pharmamar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Pfizer; PharmaMar; Roche; tesaro
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Rosalind Glasspool
Leadership - GCIG Pragmatic Trials Working Group; IGCS Patient Advocacy Group; Scottish Gynaecological Cancer Trials Group
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline
Consulting or Advisory Role - Clovis Oncology; GlaxoSmithKline; Novartis (Inst); PharmaAnd
Research Funding - Clovis Oncology
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD
Other Relationship - Allarity Therapeutics; AstraZeneca; GlaxoSmithKline; ImmunoGen/AbbVie; MATAO trial; Novartis; Verastem
 
Jacobus Pfisterer
Research Funding - GlaxoSmithKline/Tesaro (Inst); Roche Pharma AG (Inst); Roche Pharma AG (Inst)
 
Rebecca Phaeton
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Charles Anderson
Employment - Intuitive Surgical; Sarah Cannon Research Institute
Leadership - Sarah Cannon Research Institute
 
Manuel Rodrigues
Consulting or Advisory Role - Abbvie; AstraZeneca; GlaxoSmithKline; Immunocore
Speakers' Bureau - GlaxoSmithKline; Immunocore
Research Funding - Daiichi Sankyo/UCB Japan (Inst); Johnson & Johnson/Janssen (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Immunocore
 
Fernanda Musa
Leadership - Rivkin Center; Society of Gynecologic Oncology
Honoraria - MSD
Consulting or Advisory Role - AADi; Allarity Therapeutics; AstraZeneca; BioNTech; Daiichi Sankyo; DualityBio; GlaxoSmithKline
Speakers' Bureau - MSD
Research Funding - AADi (Inst); Allarity Therapeutics (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals/MorphoSys (Inst); DualityBio (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); ImmunoGen/AbbVie (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Isabelle Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; IMMUNOCORE; Immunogen; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; PMV Pharma; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Corcept Therapeutics; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Immunocore; Immunogen; Incyte; Macrogenics; Mersana; MSD Oncology; Netris Pharma; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Scorpion Therapeutics; seagen; Seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES
 
Kathleen Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Astellas Medivation; Clinical Education Alliance; Haymarket Medical Education; IDEOlogy Health; Medscape; The Clearity Foundation
Consulting or Advisory Role - AADi; Abbvie; ADC Therapeutics; AstraZeneca; BioNTech SE; Blueprint Medicines (Inst); Bristol Myers Squibb Foundation; Caris Life Sciences; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo Europe GmbH; Duality Biologics (Inst); Eisai; Elucida Oncology; Exelixis; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); immunocore; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Loxo/Lilly; Merck; Mersana (Inst); Novocure; ProfoundBio; Regeneron; Roche; Sanofi/Aventis; Schrodinger (Inst); seagen; T knife; Takeda Science Foundation; Tango Therapeutics; Third Arc; Tubulis GmbH; Verastem/Pharmacyclics; Xencor; zentalis; zymeworks
Research Funding - Amgen (Inst); artios (Inst); AstraZeneca (Inst); Daiichi Sankyo/Lilly (Inst); Immunocore (Inst); Immunogen (Inst); Merck (Inst); Regeneron (Inst); Verastem (Inst)
Other Relationship - GOG Partners (Inst)